Ahammed Hashim, MD
Pulmonary Disease · Nacogdoches, TXNPI 1235134420
Payments from drug & device makers
Across 530 payments — averaging $30.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- GSK$2K
- Boehringer Ingelheim$916
- Sanofi$641
- Mylan Specialty L.p.$598
- Actelion Pharmaceuticals US, Inc.$299
- plus $3K from 32 others
What the payments were for
- Consulting fees$5,07632%
- Travel & lodging$2842%
- Food & beverage$10,55166%
- Education$1231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 102 | $8,036 |
| GSK | 131 | $2,222 |
| Boehringer Ingelheim | 44 | $916 |
| Sanofi | 30 | $641 |
| Mylan Specialty L.p. | 31 | $598 |
| Actelion Pharmaceuticals US, Inc. | 23 | $299 |
| Sunovion Pharmaceuticals Inc. | 17 | $276 |
| Philips North America LLC | 17 | $275 |
| Regeneron Healthcare Solutions, Inc. | 12 | $245 |
| Genentech USA, Inc. | 10 | $233 |
| Paratek Pharmaceuticals, Inc. | 8 | $231 |
| Jazz Pharmaceuticals Inc. | 11 | $231 |
| Verona Pharma, Inc. | 20 | $227 |
| Amgen | 5 | $206 |
| Insmed, Inc. | 7 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $134 |
| Pfizer | 6 | $114 |
| Merck | 5 | $101 |
| Sanofi-aventis U.S. LLC | 6 | $96 |
| Inspire Medical Systems, Inc. | 2 | $92 |
| Advanced Respiratory, Inc | 5 | $88 |
| Baxter Healthcare | 4 | $76 |
| Viatris Specialty LLC | 4 | $74 |
| ANI Pharmaceuticals, Inc. | 3 | $73 |
| Pulmonx Corporation | 2 | $61 |
| Harmony Biosciences LLC | 3 | $59 |
| Electromed, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $41 |
| Kaleo, Inc. | 2 | $38 |
| Vapotherm Inc | 2 | $30 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
| Grifols USA, LLC | 1 | $23 |
| Biocryst US Sales Co., LLC | 1 | $18 |
| Optinose US, Inc. | 1 | $16 |
| Resmed Corp | 1 | $16 |
| Bayer | 1 | $15 |
| CSL Behring | 1 | $14 |
| United Therapeutics Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,033 in reported general payments places this provider in the 80th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,041 | $750,724 |
| OfevNintedanib Esylate | 49 | $641,358 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 443 | $345,599 |
| Fasenra PenBenralizumab | 31 | $193,241 |
| TezspireTezepelumab-Ekko | 17 | $181,522 |
| XolairOmalizumab | 30 | $118,570 |
| Dupixent SyringeDupilumab | 24 | $100,967 |
| NucalaMepolizumab | 26 | $98,857 |
| Dupixent PenDupilumab | 15 | $62,746 |
| Breo ElliptaFluticasone/Vilanterol | 86 | $44,076 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 64 | $43,762 |
| SymbicortBudesonide/Formoterol Fumarate | 138 | $39,106 |
| Advair HfaFluticasone Propion/Salmeterol | 100 | $36,331 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $34,188 |
| EliquisApixaban | 61 | $26,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,222 | $949,2171,285 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $916 | $702,006141 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $8,036 | $578,057632 claims |
| PfizerEliquis | $114 | $26,73361 claims |
| MerckDulera | $101 | $9,25228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Nacogdoches
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.